FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections
The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia. An...
Merck Completes € 180 Million Investment to Expand Schnelldorf Distribution Center
DARMSTADT, Germany--(BUSINESS WIRE)--Merck opened its expanded Life Science distribution center in Schnelldorf, Germany. The € 180 investment added 25,000 square meters to the site.
Merck (MRK) Ascends But Remains Behind Market: Some Facts to Note
The latest trading day saw Merck (MRK) settling at $129.45, representing a +0.57% change from its previous close.
Merck Signs MoU with KAIST to Advance Scientific Collaboration
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Tec...
Merck to Buy Eye Drug Startup For Up to $3 Billion. It's Doubling Down on Deals.
The pharmaceutical company agreed to buy eye drug company Eyebiotech for up to $3 billion as it moves to diversify its pipeline and intensifies its acquisition efforts.
Merck to acquire eye drug company EyeBio for up to $3 bln
Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3 billion, in the latest acquisition by the U.S. drugmaker as it looks to boost growth.
Merck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnol...
Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports
Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the Wall Street...
Merck Announces Third-Quarter 2024 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2024 Dividend.
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and ...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline.
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
Merck stops skin cancer combination therapy testing in late-stage study
Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most ...
The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
A commonly used strategy for investing is sector rotation. This involves the movement of funds from one sector to another based on macroeconomic and other factors.
Here's Why Merck (MRK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024.
Related Companies